prikaz prve stranice dokumenta Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey
  Download
PDF 2.44 MB
Scientific paper - Original scientific paper
Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey
Bone Marrow Transplantation, 58 (2023), 6; 647-658. https://doi.org/10.1038/s41409-023-01943-3
Passweg, Jakob R.; Baldomero, Helen; Ciceri, Fabio; Corbacioglu, Selim; de la Cámara, Rafael; Dolstra, Harry; Glass, Bertram; Greco, Raffaella; McLornan, Donal P.; Neven, Bénédicte; de Latour, Régis Peffault; Perić, Zinaida; Ruggeri, Annalisa; Snowden, John A.; Sureda, Anna More authors...

Cite this document

Passweg, J. R., Baldomero, H., Ciceri, F., Corbacioglu, S., de la Cámara, R., Dolstra, H. ... Sureda, A. (2023). Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplantation, 58. (6), 647-658. doi: 10.1038/s41409-023-01943-3

Passweg, Jakob R., et al. "Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey." Bone Marrow Transplantation, vol. 58, no. 6, 2023, pp. 647-658. https://doi.org/10.1038/s41409-023-01943-3

Passweg, Jakob R., Helen Baldomero, Fabio Ciceri, Selim Corbacioglu, Rafael de la Cámara, Harry Dolstra, Bertram Glass, et al. "Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey." Bone Marrow Transplantation 58, no. 6 (2023): 647-658. https://doi.org/10.1038/s41409-023-01943-3

Passweg, J. R., et al. (2023) 'Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey', Bone Marrow Transplantation, 58(6), pp. 647-658. doi: 10.1038/s41409-023-01943-3

Passweg JR, Baldomero H, Ciceri F, Corbacioglu S, de la Cámara R, Dolstra H, and sur.. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplantation [Internet]. 2023 June [cited 2024 May 05];58(6):647-658. doi: 10.1038/s41409-023-01943-3

J. R. Passweg, et al., "Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey", Bone Marrow Transplantation, vol. 58, no. 6, pp. 647-658, June 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:854441. [Accessed: 05 May 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey
AuthorJakob R. Passweg
AuthorHelen Baldomero
AuthorFabio Ciceri
AuthorSelim Corbacioglu
AuthorRafael de la Cámara
AuthorHarry Dolstra
AuthorBertram Glass
AuthorRaffaella Greco
AuthorDonal P. McLornan
AuthorBénédicte Neven
AuthorRégis Peffault de Latour
AuthorZinaida Perić
AuthorAnnalisa Ruggeri
AuthorJohn A. Snowden
AuthorAnna Sureda
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
In 2021, 47,412 HCT (19,806 (42%) allogeneic and 27,606 (58%) autologous) in 43,109 patients were reported by 694 European centers. 3494 patients received advanced cellular therapies, 2524 of which were CAR-T treatments, an additional 3245 received DLI. Changes compared to the previous year were CAR-T treatment (+35%), allogeneic HCT +5.4%, autologous HCT +3.9%, more pronounced in non-malignant disorders. Main indications for allogeneic HCT were myeloid malignancies 10,745 (58%), lymphoid malignancies 5127 (28%) and non-malignant disorders 2501 (13%). Main indications for autologous HCT were lymphoid malignancies 22,129 (90%) and solid tumors 1635 (7%). In allogeneic HCT, use of haploidentical donors decreased by −0.9% while use of unrelated and sibling donors increased by +4.3% and +9%. Cord blood HCT decreased by −5.8%. Pediatric HCT increased overall by +5.6% (+6.9% allogeneic and +1.6% autologous). Increase in the use of CAR-T was mainly restricted to high-income countries. The drop in HCT activity reported in 2020 partially recovered in 2021, the second year of the SARS-CoV-2 pandemic. The transplant community confronted with the pandemic challenge, continued in providing patients access to treatment. This annual EBMT report reflects current activities useful for health care resource planning.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBone Marrow Transplantation
Numberingvol. 58, no. 6, pp. 647-658
p-ISSN0268-3369
e-ISSN1476-5365
DOIhttps://doi.org/10.1038/s41409-023-01943-3
URN:NBNurn:nbn:hr:105:854441
Publication2023-06
Document URLhttps://www.nature.com/articles/s41409-023-01943-3
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-01-12 09:05:26